Talquetamab

Therapeutic indications

Talquetamab is indicated for:

Relapsed and refractory multiple myeloma

Population group: only adults (18 years old or older)

Talquetamab is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Step-up phase with 1 dose once every 2-4 days from 0.01 to 0.4 mg/kg or 0.01 to 0.8 mg/kg and thereafter 0.4 mg/kg once a week or 0.8 mg/kg once every 2 weeks respectively

Contraindications

Talquetamab is contraindicated in the following cases:

Pregnancy

Lactation

Effects on ability to drive and use machines

Active serious infection

Infectious disease

Live viral vaccines

Live organism vaccines

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.